The androgen receptor remains a key player in metastatic hormone-refractory prostate cancer. Implications for new treatments

Journal of B.U.ON.

Volumn 19, Issue 2, 2014, Pages 357-364

  Nemes, Adina ^a   Tomuleasa, Ciprian ^a,b   Kacso, Gabriel ^a,b,c  

^a THE ONCOLOGY INSTITUTE PROF DR ION CHIRICUTA   (Romania)

^b IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c Amethyst Medical Clinic   (Romania)

Author keywords

Androgen receptor; Hormone refractory; Prostate cancer

Indexed keywords

ABIRATERONE ACETATE; ANDROGEN RECEPTOR; ANTIANDROGEN; BICALUTAMIDE; CABAZITAXEL; CABOZANTINIB; CETUXIMAB; DEXAMETHASONE; DOCETAXEL; ENZALUTAMIDE; KETOCONAZOLE; METFORMIN; ORTERONEL; TESTOSTERONE;

ANDROGEN DEPRIVATION THERAPY; ANTIANDROGEN THERAPY; CANCER CHEMOTHERAPY; CANCER THERAPY; CASTRATION RESISTANT PROSTATE CANCER; DRUG CHOICE; DRUG USE; GENE MUTATION; HUMAN; MALE; ORCHIECTOMY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TESTOSTERONE BLOOD LEVEL;

GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RECEPTORS, ANDROGEN;

EID: 84904212241     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Sternberg C, Fizazi K. The relevance of continued medical castration for patients with castration resistant prostate cancer. Ann Urol 2011;2:34-39.
2. Jemal A, Bray F, Center MM et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
3. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010;46:765-781.
4. Shore ND, Abrahamsson PA, Anderson J, Crawford ED, Lang P. New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists. Prostate Cancer 2013;16:7-15.
5. Scher HI, Eisenberger M, D'Amico AV et al. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising PSA: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 2004;22:537-556. (Pubitemid 41079783)
6. Hu R, Denmeade SR, Luo J. Molecular processes leading to aberrant androgen receptor signalling and castration resistance in prostate cancer. Expert Rev Endocrinol Metab 2010;5:753-764.
7. Brickmann BJ, Blok LJ, de Ruiter PE et al. Mechanisms of androgen receptor activation and function. J Steroid Biochem Mol Biol 1999;69:307-313. (Pubitemid 29305551)
8. Oudard S. Progress in emerging therapies for advanced prostate cancer. Cancer Treat Rev (2012), http://dx.doi.org/10.1016/j.ctrv.2012.09.005.
9. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001;1:34-45. (Pubitemid 33741879)
10. Mostaghel EA, Page ST, Lin DW et al. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res 2007;67:5033-5041. (Pubitemid 46910214)
11. Gregory CW, He B, Johnson RT et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 2001;61:4315-4319. (Pubitemid 32685750)
12. Rocchi P, Beraldi E, Ettinder S et al. Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis. Cancer Res 2005; 65: 1083-1093.
13. Taplin ME, Rajeshkumar B, Halabi S et al. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol 2003;21:2673-2678. (Pubitemid 46606310)
14. Dehm SM, Schmidt LJ, Heemers HV et al. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 2008; 68:5469-5477.
15. Guo Z, Yang X, Sun F et al. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res 2009;69:2305-2313.
16. Curing Z., Hobisch A., Cronauer MV et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 1994;54:5474-5478.
17. Pienta KJ, Bradley D. Mechanism underlying the development of androgen independent prostate cancer. Clin Cancer Res 2006;12:1665-1671.
18. Colombel M, Symmans F, Gil S et al. Detection of the apoptosis-supressing oncoprotein bcl-2 in hormone-refractory human prostate cancer. Am J Pathol 1993;143:390-400. (Pubitemid 24058194)
19. Saacs JT. The biology of hormone refractory prostate cancer. Why does it develop? Urol Clin North Am 1999;26:263-273.
20. Labrie F, Belanger A, Dupont A et al. Science behind total androgen blockade: from gene to combination therapy. Clin Invest Med 1993;16:475-492. (Pubitemid 24111962)
21. Kucuk O, Fisher E, Moinpour CM et al. Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: a Southwest Oncology Group study (SWOG 9235). Urology 2001;58:53-58. (Pubitemid 32633935)
22. Scher HI, Fizazi K, Saad F et el. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367:1187-1197.
23. Weckemann D, Harzmann R. Hormone therapy in prostate cancer: LHRH antagonists versus LHRH analogues. Eur Urol 2004;46:279-283.
24. Trachtenberg J, Gittleman M, Steidle C et al. A phase III multicentre, open label, randomized study of abarelix versus leuproline plus daily antiandrogen in men with prostate cancer. J Urol 2002;167:1670-1674. (Pubitemid 34240698)
25. Tombal B, Miller K, Boccon-Gibod L et al. Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics. Eur Urol 2010;57:836-842.
26. Tombal B, Berges R. How good do current LHRH agonists control testosterone? Can this be improved with Eligard? Eur Urol Supplements 2005;4:30-36. (Pubitemid 41423590)
27. Sartoro AO, Tangen CM, Hussain MH et al. Antiandrogen withdrawal in castrate- refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426). Cancer 2008;112:2393-2400.
28. Aljada A, Mousa SA. Metformin and neoplasia: implications and indications. Pharmacol Ther 2012;133:108-115.
29. Cathomas R, Rothermundt C, Klingbiel D et al. Efficacy of Cetuximab in Metastatic Castration-Resistant Prostate Cancer Might Depend on EGFR and PTEN Expression: Results from a Phase II Trial (SAKK 08/07). Clin Cancer Res 2012;18:6049-6057.
30. Smith DC, Smith MR, Sweeney C et al. Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial. J Clin Oncol 2012;31:412-419.
31. Zielinski RR, Eigl BJ, Chi KN. Targeting the apoptosis pathway in prostate cancer. Cancer J 2013;19:79-89.
32. Oudard S, Banu E, Scotte E et al. Prostate specific antigen doubling time before onset of chemotherapy as a predictor for survival for hormone-refractory prostate cancer patients. Ann Oncol 2007;18:1828-1833. (Pubitemid 350111569)
33. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351:1502-1512. (Pubitemid 39315317)
34. Petrylak DP, Tangen CM, Hussian MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-1520. (Pubitemid 39315318)
35. de Bono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial. Lancet 2010;376:1147-1154.
36. Zhu ML, Horbinski CM, Garzotto M et al. Tubulin-targeted chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res 2010;70:7992-8002.
37. Mezynski J, Pezaro C, Bianchini D et al. Antitumor activity of Docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? Ann Oncol 2012;23:2943-2947.
38. Zhang TY, Agarwal N, Sonpavde G et al. Management of castrate resistant prostate cancer -recent advances and optimal sequence of treatments. Curr Urol Rep 2013;14:174-183.
39. Loriot Y, Fizazi K. Towards random sequencing or precision medicine in castration-resistant prostate cancer. Eur Urol 2014;65:37-38.
40. Small EJ, Halabi S, Dawson NA et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial(CALGB 9583). J Clin Oncol 2004;22:1025-1033. (Pubitemid 41095034)
41. Venkitaraman R, Thomas K, Huddart RA et al. Efficacy of low-dose dexamethasone in castration-refractory prostate cancer. BJU Int 2008;101:440-443. (Pubitemid 351160930)
42. Komiya A, Shimbo M, Suzuki H et al. Oral low-dose dexamethasone for androgen-independent prostate cancer patients. Oncol Lett 2010;1:73-79.
43. Attard G, Reid AH, A'Hern R et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009;27:3742-3748.
44. Fizazi K, Scher HI, Molina A et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COUAA-301 randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 2012;13:983-992.
45. Ryan CJ, Smith MR, de Bono JS et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368:138-148.
46. Efstathiou E, Titus M, Tsavachidou D et al. Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. J Clin Oncol 2012;30:637-643.
47. Rathkopf D, Scher HI. Androgen receptor antagonists in castration-resistant prostate cancer. Cancer J 2013;19:43-49.
48. Schrader AJ, Boegemann M, Ohlmann CH et al. Enzalutamide in castration-resistant prostate cancer patients progressing after Docetaxel and Abiraterone. Eur Urol 2014;65:30-36.
49. Loriot Y, Bianchini D, Ileana E et al. Antitumour activity of abiraterone acetate against metastatic castration resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Ann Oncol 2013;24:1807-1812.
50. Noonan KL, North S, Bitting RL et al. Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann Oncol 2013;24:1802-1807.